2024
A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors
Ouattara S, Hien D, Nao E, Paré P, Guissou E, Cohuet A, Morlais I, Yerbanga R, Dabiré K, Ouédraogo J, Mouline K, Lefèvre T. A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors. Malaria Journal 2024, 23: 135. PMID: 38711028, PMCID: PMC11075210, DOI: 10.1186/s12936-024-04969-0.Peer-Reviewed Original ResearchConceptsDirect membrane feeding assaysGametocyte densityHuman-to-mosquito transmissionDonor bloodLow gametocyte densitiesMembrane feeding assaysPlasmodium falciparum gametocytesTransmission-blocking interventionsWhole bloodInfection rateFalciparum gametocytesInfectious reservoirNaive serumAsymptomatic individualsMosquito infectionHuman donorsRemoval of plasmaEndemic countriesSerumPlasmodiumParasite isolatesInfectionBlood treatmentGametocytesPlasma volumeEx vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Somé A, Conrad M, Kabré Z, Fofana A, Yerbanga R, Bazié T, Neya C, Somé M, Kagambega T, Legac J, Garg S, Bailey J, Ouédraogo J, Rosenthal P, Cooper R. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents And Chemotherapy 2024, 68: e01534-23. PMID: 38411062, PMCID: PMC10989024, DOI: 10.1128/aac.01534-23.Peer-Reviewed Original ResearchResistance to antifolatesUncomplicated malariaEx vivo drug susceptibilityArtemisinin partial resistanceMonthly sulfadoxine-pyrimethaminePfcrt K76TPfK13 propeller domainResistance-mediating polymorphismsSeasonal malaria chemopreventionTreating uncomplicated malariaResistance to cycloguanilHigh-level resistancePlasmodium falciparum</i>A581GA613S mutationsPfdhps mutationsPfmdr1 N86YArtemether-lumefantrineK76TSulfadoxine-pyrimethamineMalaria chemopreventionPrevent malariaBobo-DioulassoDrug susceptibilityPrincipal therapyThe public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
Schmit N, Topazian H, Natama H, Bellamy D, Traoré O, Somé M, Rouamba T, Tahita M, Bonko M, Sourabié A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo M, Lopez F, Charles G, McCain K, Ouedraogo J, Hamaluba M, Olotu A, Dicko A, Tinto H, Hill A, Ewer K, Ghani A, Winskill P. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. The Lancet Infectious Diseases 2024, 24: 465-475. PMID: 38342107, DOI: 10.1016/s1473-3099(23)00816-2.Peer-Reviewed Original ResearchDisability-adjusted life yearsClinical malariaMalaria vaccineClinical casesVaccine introductionVaccinated childrenVaccine efficacyYears of follow-upPhase 2b trialPhase 3 trialSub-Saharan AfricaSurrogate of protectionIncremental costAntibody titresPublic health impactSerum Institute of IndiaBill &Cost-effectiveness ratioChildren aged 2Dose pricesMalaria deathsMelinda Gates FoundationNIHR Oxford Biomedical Research CentreFollow-upUK Medical Research CouncilSafety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo M, Dicko A, Tinto H, Ouédraogo J, Hamaluba M, Olotu A, Beaumont E, Lopez F, Natama H, Weston S, Chemba M, Compaore Y, Issiaka D, Salou D, Some A, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood B, Ewer K, Bradley J, Kulkarni P, Shaligram U, Hill A, Group R, Mahamar A, Sanogo K, Sidibe Y, Diarra K, Samassekou M, Attaher O, Tapily A, Diallo M, Dicko O, Kaya M, Maguiraga S, Sankare Y, Yalcouye H, Diarra S, Niambele S, Thera I, Sagara I, Sylla M, Dolo A, Misidai N, Simando S, Msami H, Juma O, Gutapaka N, Paul R, Mswata S, Sasamalo I, Johaness K, Sultan M, Alexander A, Kimaro I, Lwanga K, Mtungwe M, Khamis K, Rugarabam L, Kalinga W, Mohammed M, Kamange J, Msangi J, Mwaijande B, Mtaka I, Mhapa M, Mlaganile T, Mbaga T, Yerbanga R, Samtouma W, Sienou A, Kabre Z, Ouedraogo W, Yarbanga G, Zongo I, Savadogo H, Sanon J, Compaore J, Kere I, Yoni F, Sanre T, Ouattara S, Provstgaard-Morys S, Woods D, Snow R, Amek N, Ngetsa C, Ochola-Oyier L, Musyoki J, Munene M, Mumba N, Adetifa U, Muiruri C, Mwawaka J, Mwaganyuma M, Ndichu M, Weya J, Njogu K, Grant J, Webster J, Lakhkar A, Ido N, Traore O, Tahita M, Bonko M, Rouamba T, Ouedraogo D, Soma R, Millogo A, Ouedraogo E, Sorgho F, Konate F, Valea I. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet 2024, 403: 533-544. PMID: 38310910, DOI: 10.1016/s0140-6736(23)02511-4.Peer-Reviewed Original ResearchConceptsClinical malaria episodesPhase 3 trialMalaria episodesMonths age groupAdverse eventsVaccine efficacyClinical malariaMalaria vaccineDouble-blindMalaria transmissionControl vaccineAsn-Ala-Asn-ProAge groupsStandard sitesMonths of follow-upAfrican childrenPerennial malaria transmissionBurden of malariaSeasonal malaria transmissionMalaria transmission intensityPhase 2b trialInjection site painFrequent adverse eventsCo-primary endpointsVaccine-induced antibodies
2023
Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa.
Djimde M, Kayentao K, Tshiongo J, Fofana B, Arama C, Sirima S, Ouedraogo J, Beavogui A, Sagara I, Dicko A, Mens P, Schallig H, Djimde A. Variation in neutrophil levels and artemisinin-based combination therapy efficacy in West-Africa. The Journal Of Infection In Developing Countries 2023, 17: 1337-1345. PMID: 37824364, DOI: 10.3855/jidc.17089.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyNormal neutrophil countsPolymorphonuclear neutrophilsDay 28Neutropenia groupPyronaridine-ArtesunateNeutrophil countNeutrophil levelsDifferent artemisinin-based combination therapiesRole of PMNsCombination therapy efficacyP. falciparum parasitemiaPositive blood smearPlasmodium falciparum parasitemiaLevels of neutrophilsAL armASAQ armProspective longitudinalRecurrent parasitemiaCombination therapyNeutrophil rateNeutropenia patientsNormal ratePatientsPathogen clearanceThe impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Guissou R, Amaratunga C, de Haan F, Tou F, Cheah P, Yerbanga R, Moors E, Dhorda M, Tindana P, Boon W, Dondorp A, Ouédraogo J. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malaria Journal 2023, 22: 269. PMID: 37705004, PMCID: PMC10498571, DOI: 10.1186/s12936-023-04705-0.Peer-Reviewed Original ResearchConceptsDepth interviewsGroup discussionsNational policy makersDrug marketBurkina FasoFocus group discussionsPolicy publicationsPublic policyCommunity membersFunding systemPolicy makersAfrican countriesPolicyAnti-malarial policyMarket characteristicsAnti-malarial marketInterviewsRepresentative sampleGrey literatureMarketFasoPerspectiveEmergenceTerms of availabilityDiscussionFacteurs influençant l'observation de la deuxième et troisième dose pendant la chimioprévention du paludisme saisonnier (CPS) - Une étude quantitative au Burkina Faso, Mali et Niger
Somé A, Zongo I, Sagara I, Ibrahim A, Ahanhanzo C, Agbanouvi-Agassi E, Sayi D, Paré L, Kabré Z, Nikiéma F, Bazié T, Ouédraogo S, Sombié I, Dicko A, Adehossi E, Ouédraogo J, Dabiré K. Facteurs influençant l'observation de la deuxième et troisième dose pendant la chimioprévention du paludisme saisonnier (CPS) - Une étude quantitative au Burkina Faso, Mali et Niger. Revue D'Epidémiologie Et De Santé Publique 2023, 71: 101880. DOI: 10.1016/j.respe.2023.101880.Peer-Reviewed Original ResearchSeasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
Dicko A, Ouedraogo J, Zongo I, Sagara I, Cairns M, Yerbanga R, Issiaka D, Zoungrana C, Sidibe Y, Tapily A, Nikièma F, Sompougdou F, Sanogo K, Kaya M, Yalcouye H, Dicko O, Diarra M, Diarra K, Thera I, Haro A, Sienou A, Traore S, Mahamar A, Dolo A, Kuepfer I, Snell P, Grant J, Webster J, Milligan P, Lee C, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Chandramohan D, Greenwood B. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. The Lancet Infectious Diseases 2023, 24: 75-86. PMID: 37625434, DOI: 10.1016/s1473-3099(23)00368-7.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionPhase 3 trialClinical malariaAlone groupMalaria Vaccine InitiativeMalaria chemopreventionSeasonal vaccinationProtective efficacyCombined groupPATH Malaria Vaccine InitiativeGlobal Health TrialsPrimary trial endpointSeasonal malaria transmissionSingle intervention groupSupplementary Materials sectionBougouni DistrictCause deathModified intentionProtocol populationControl vaccineMalaria vaccinationMalarial anemiaSevere malariaBlood transfusionHospital admissionWhy small-quantity lipid-based nutrient supplements should be integrated into comprehensive strategies to prevent child undernutrition in nutritionally vulnerable populations: response to Gupta et al.’s commentary
Dewey K, Stewart C, McDonald C, Wessells K, Arnold C, Prado E, Abbeddou S, Adu-Afarwuah S, Arnold B, Ashorn P, Ashorn U, Ashraf S, Becquey E, Black R, Brown K, Christian P, Colford J, Fernald L, Galasso E, Hallamaa L, Hess S, Humphrey J, Huybregts L, Iannotti L, Jannat K, Jimenez E, Lartey A, Le Port A, Leroy J, Luby S, Maleta K, Matchado A, Matias S, Mbuya M, Mridha M, Paul R, Okronipa H, Ouédraogo J, Pickering A, Prendergast A, Ruel M, Shaikh S, Weber A, Wolff P. Why small-quantity lipid-based nutrient supplements should be integrated into comprehensive strategies to prevent child undernutrition in nutritionally vulnerable populations: response to Gupta et al.’s commentary. World Nutrition 2023, 14: 79-85. DOI: 10.26596/wn.202314279-85.Peer-Reviewed Original ResearchEthical, regulatory and market related aspects of deploying Triple Artemisinin-Based Combination Therapies for malaria treatment in Africa
Bolarinwa O, Mokuolu O, Guissou R, Tou F, Ouedraogo J, Boon W, Moors E, Dhorda M, Amaratunga C, Cheah P, Tindana P, Haan F, Dondorp A. Ethical, regulatory and market related aspects of deploying Triple Artemisinin-Based Combination Therapies for malaria treatment in Africa. The Global Health Network Collections 2023 DOI: 10.21428/3d48c34a.4e367b81.Peer-Reviewed Original ResearchSeasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Roh M, Zongo I, Haro A, Huang L, Somé A, Yerbanga R, Conrad M, Wallender E, Legac J, Aweeka F, Ouédraogo J, Rosenthal P. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. The Journal Of Infectious Diseases 2023, 228: 926-935. PMID: 37221018, PMCID: PMC10547452, DOI: 10.1093/infdis/jiad172.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDrug levelsMonths of ageOdds ratioHigh-level SP resistanceSP-AQCase-control studyConditional logistic regressionLow drug levelsPrevalence of mutationsDrug resistance markersCase-control designResistance markersIncident malariaParasitemic childrenMalaria chemopreventionAntimalarial resistanceChildren 6Health facilitiesSP resistanceChildren 3Malaria incidenceDrug resistanceMalariaLogistic regressionTracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial sectionCost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso
Diawara H, Bocoum F, Dicko A, Levin A, Lee C, Koita F, Ouédraogo J, Guissou R, Yabré S, Traoré S, Morgan W, Pecenka C, Baral R. Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Global Health 2023, 8: e011316. PMID: 37068848, PMCID: PMC10111920, DOI: 10.1136/bmjgh-2022-011316.Peer-Reviewed Original ResearchConceptsVaccine deliverySeasonal vaccinationMalaria vaccineMalaria transmissionSeasonal malaria transmissionRoutine Expanded ProgrammeResource use dataRoutine EPINew vaccine introductionSeasonal malariaVaccine introductionMain cost driversHealth facilitiesExpanded ProgrammeVaccine priceVaccine rolloutMass campaignsService deliveryYoung childrenVaccinationCost consequencesBurkina FasoFinancial costsVaccineDelivery approachPf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
MalariaGEN, Hamid M, Abdelraheem M, Acheampong D, Ahouidi A, Ali M, Almagro-Garcia J, Amambua-Ngwa A, Amaratunga C, Amenga-Etego L, Andagalu B, Anderson T, Andrianaranjaka V, Aniebo I, Aninagyei E, Ansah F, Ansah P, Apinjoh T, Arnaldo P, Ashley E, Auburn S, Awandare G, Ba H, Baraka V, Barry A, Bejon P, Bertin G, Boni M, Borrmann S, Bousema T, Bouyou-Akotet M, Branch O, Bull P, Cheah H, Chindavongsa K, Chookajorn T, Chotivanich K, Claessens A, Conway D, Corredor V, Courtier E, Craig A, D'Alessandro U, Dama S, Day N, Denis B, Dhorda M, Diakite M, Djimde A, Dolecek C, Dondorp A, Doumbia S, Drakeley C, Drury E, Duffy P, Echeverry D, Egwang T, Enosse S, Erko B, Fairhurst R, Faiz A, Fanello C, Fleharty M, Forbes M, Fukuda M, Gamboa D, Ghansah A, Golassa L, Goncalves S, Harrison G, Healy S, Hendry J, Hernandez-Koutoucheva A, Hien T, Hill C, Hombhanje F, Hott A, Htut Y, Hussein M, Imwong M, Ishengoma D, Jackson S, Jacob C, Jeans J, Johnson K, Kamaliddin C, Kamau E, Keatley J, Kochakarn T, Konate D, Konaté A, Kone A, Kwiatkowski D, Kyaw M, Kyle D, Lawniczak M, Lee S, Lemnge M, Lim P, Lon C, Loua K, Mandara C, Marfurt J, Marsh K, Maude R, Mayxay M, Maïga-Ascofaré O, Miotto O, Mita T, Mobegi V, Mohamed A, Mokuolu O, Montgomery J, Morang’a C, Mueller I, Murie K, Newton P, Duc T, Nguyen T, Nguyen T, Kim T, Van H, Noedl H, Nosten F, Noviyanti R, Ntui V, Nzila A, Ochola-Oyier L, Ocholla H, Oduro A, Omedo I, Onyamboko M, Ouedraogo J, Oyebola K, Oyibo W, Pearson R, Peshu N, Phyo A, Plowe C, Price R, Pukrittayakamee S, Quang H, Randrianarivelojosia M, Rayner J, Ringwald P, Rosanas-Urgell A, Rovira-Vallbona E, Ruano-Rubio V, Ruiz L, Saunders D, Shayo A, Siba P, Simpson V, Sissoko M, Smith C, Su X, Sutherland C, Takala-Harrison S, Talman A, Tavul L, Thanh N, Thathy V, Thu A, Toure M, Tshefu A, Verra F, Vinetz J, Wellems T, Wendler J, White N, Whitton G, Yavo W, van der Pluijm R. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples. Wellcome Open Research 2023, 8: 22. PMID: 36864926, PMCID: PMC9971654, DOI: 10.12688/wellcomeopenres.18681.1.Peer-Reviewed Original Research
2022
Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein
Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck J, Lucas C, Klein J, Filler R, Strine M, Sy M, Deme A, Badiane A, Dieye B, Ndiaye I, Diedhiou Y, Mbaye A, Diagne C, Vigan-Womas I, Mbengue A, Sadio B, Diagne M, Moore A, Mangou K, Diallo F, Sene S, Pouye M, Faye R, Diouf B, Nery N, Costa F, Reis M, Muenker M, Hodson D, Mbarga Y, Katz B, Andrews J, Campbell M, Srivathsan A, Kamath K, Baum-Jones E, Faye O, Sall A, Vélez J, Cappello M, Wilson M, Ben-Mamoun C, Tedder R, McClure M, Cherepanov P, Somé F, Dabiré R, Moukoko C, Ouédraogo J, Boum Y, Shon J, Ndiaye D, Wisnewski A, Parikh S, Iwasaki A, Wilen C, Ko A, Ring A, Bei A. Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. Scientific Reports 2022, 12: 22175. PMID: 36550362, PMCID: PMC9778468, DOI: 10.1038/s41598-022-26709-7.Peer-Reviewed Original ResearchConceptsCross-reactive antibodiesSARS-CoV-2Positive SARS-CoV-2 antibody resultsPositive SARS-CoV-2 antibodiesSARS-CoV-2 reactivitySARS-CoV-2 antibodiesAcute malaria infectionSpike proteinAntibody test resultsPre-pandemic samplesMalaria-endemic countriesPopulation-level immunityMalaria-endemic regionsSpike S1 subunitNon-endemic countriesSARS-CoV-2 spike proteinSARS-CoV-2 proteinsPopulation-level exposureCOVID-19 transmissionMalaria exposureFalse-positive resultsMalaria infectionDisease burdenPlasmodium infectionAntibody resultsPrevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case)
López-Farfán D, Yerbanga R, Parres-Mercader M, Torres-Puente M, Gómez-Navarro I, Sanou M, Yao A, Ouédraogo J, Comas I, Irigoyen N, Gómez-Díaz E. Prevalence of SARS-CoV-2 and co-infection with malaria during the first wave of the pandemic (the Burkina Faso case). Frontiers In Public Health 2022, 10: 1048404. PMID: 36579069, PMCID: PMC9791192, DOI: 10.3389/fpubh.2022.1048404.Peer-Reviewed Original ResearchSeasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study
Thompson H, Hogan A, Walker P, Winskill P, Zongo I, Sagara I, Tinto H, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B, Cairns M, Ghani A. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study. The Lancet Global Health 2022, 10: e1782-e1792. PMID: 36400084, DOI: 10.1016/s2214-109x(22)00416-8.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionSeasonal transmission settingsS vaccinationTransmission settingsTransmission seasonFull therapeutic coursePhase 3b trialSevere malaria outcomesUK Medical Research CouncilEstimates of casesDuration of protectionMalaria transmission intensityEntomological inoculation rateGreater absolute reductionMedical Research CouncilTransmission intensitySignificant additional protectionAge-based strategiesMalaria outcomesClinical malariaMalaria chemopreventionVaccination scheduleMalaria vaccineClinical incidenceClinical trialsPreventive small-quantity lipid-based nutrient supplements reduce severe wasting and severe stunting among young children: an individual participant data meta-analysis of randomized controlled trials
Dewey K, Arnold C, Wessells K, Prado E, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold B, Ashorn P, Ashorn U, Ashraf S, Becquey E, Brown K, Christian P, Colford J, Dulience S, Fernald L, Galasso E, Hallamaa L, Hess S, Humphrey J, Huybregts L, Iannotti L, Jannat K, Lartey A, Le Port A, Leroy J, Luby S, Maleta K, Matias S, Mbuya M, Mridha M, Nkhoma M, Null C, Paul R, Okronipa H, Ouédraogo J, Pickering A, Prendergast A, Ruel M, Shaikh S, Weber A, Wolff P, Zongrone A, Stewart C. Preventive small-quantity lipid-based nutrient supplements reduce severe wasting and severe stunting among young children: an individual participant data meta-analysis of randomized controlled trials. American Journal Of Clinical Nutrition 2022, 116: 1314-1333. PMID: 36045000, DOI: 10.1093/ajcn/nqac232.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsLipid-based nutrient supplementsSevere wastingIndividual participant dataParticipant dataPassive control armStudy-level characteristicsSevere stuntingMo of ageFixed-effects modelNutrient supplementsHealthy child growthControl armChildren 6Inclusion criteriaEffect modifiersPreventive interventionsChild wastingGreater burdenSubgroup estimatesWastingChild growthYoung childrenStuntingRelative reductionPrevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study
Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K, Ceesay S, Bazie T, Kolie F, Lamine M, Cairns M, Snell P, Scott S, Diallo A, Merle C, NDiaye J, Razafindralambo L, Moroso D, Ouedraogo J, Zongo I, Kessely H, Doumagoum D, Bojang K, Ceesay S, Loua K, Maiga H, Dicko A, Sagara I, Laminou I, Ogboi S, Eloike T, Milligan P, Sutherland C. Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. The Lancet Infectious Diseases 2022, 23: 361-370. PMID: 36328000, DOI: 10.1016/s1473-3099(22)00593-x.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionResistance-associated variantsParasite carriageSurvey-weighted prevalenceMalaria transmission seasonQuantitative PCRPrevalence ratiosP falciparumGenomic surveillance studyChemoprevention drugsBlood samplesSurveillance studyTransmission seasonChemopreventionPlasmodium falciparumAmodiaquinePrevalenceMDR1Variant haplotypeSequencing of isolatesSignificant reductionChildrenPyrimethamineCommunity surveyThe duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone
Cairns M, Barry A, Zongo I, Sagara I, Yerbanga S, Diarra M, Zoungrana C, Issiaka D, Sienou A, Tapily A, Sanogo K, Kaya M, Traore S, Diarra K, Yalcouye H, Sidibe Y, Haro A, Thera I, Snell P, Grant J, Tinto H, Milligan P, Chandramohan D, Greenwood B, Dicko A, Ouedraogo J. The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone. BMC Medicine 2022, 20: 352. PMID: 36203149, PMCID: PMC9540742, DOI: 10.1186/s12916-022-02536-5.Peer-Reviewed Original ResearchConceptsDuration of protectionSeasonal malaria chemopreventionClinical malariaMalaria chemopreventionProtective efficacyDifferent vaccine delivery systemsFlexible parametric survival modelsMalaria transmission seasonOverall protective efficacyVaccine delivery systemChild clusteringBooster dosesSeasonal vaccinationMalaria vaccinationSevere malariaDelivery intervalParametric survival modelsCox regressionMalaria vaccinePrimary seriesRecent trialsIntervention groupConclusionsThe efficacyAS01ECox model